Open AccessDABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY
Author(s) -
Н. А. Новикова,
А. Н. Воловченко,
Д. А. Парфенов
Publication year - 2019
Publication title -
aterotromboz
Language(s) - English
Resource type - Journals
eISSN - 2658-5952
pISSN - 2307-1109
DOI - 10.21518/2307-1109-2019-1-53-61
Subject(s) - dabigatran , idarucizumab , clinical practice , clinical trial , medicine , patient safety , intensive care medicine , risk analysis (engineering) , warfarin , health care , family medicine , atrial fibrillation , political science , law
The widespread use of new oral anticoagulants in clinical practice requires improving the safety of medication use, i.e. the use of specific reversal agents, if necessary. Idarucizumab, a humanied monoclonal antibody fragment, is the first reversal agent authorized in our country that binds to dabigatran. Its efficacy and safety have been validated in several clinical trials, and its use gains experience in real clinical practice.